matter-closing-memo.docx

1018-00002 · Penterra Pharmaceuticals Corp · Closing

matter-closing-memo.docx DOCUMENT M&A / Corporate

1 / 12 → ✕

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege, the work-product doctrine, and all other applicable privileges and protections. It is intended solely for use by the named recipients and authorized personnel of Calderwood & Harkness LLP in connection with Matter No. 1018-00002. Any unauthorized review, use, disclosure, or distribution is strictly prohibited.

CALDERWOOD & HARKNESS LLP 600 Lexington Avenue New York, NY 10022

INTERNAL MEMORANDUM

February 22, 2024

TO: Leonard Cross, Responsible Partner (Tax) Nathaniel Bower, Billing Partner (Bankruptcy & Restructuring)

FROM: Jeffrey Park, Lead Associate (Litigation (General))

CC: Audrey Zhou, Working Associate (Capital Markets)

RE: Matter Closing Memorandum — Penterra Pharmaceuticals Corp. / FDA OPDP Inquiry OPDP-2023-1847

MATTER NUMBER: 1018-00002

CLIENT: Penterra Pharmaceuticals Corp. (NYSE: PTPH) 480 Overlook Drive, Suite 700 Summit, NJ 07901

CLIENT CONTACT: Margaret Tan, Executive Vice President & General Counsel

MATTER STATUS: Closed — Completed

I. PURPOSE

This memorandum formally memorializes the closing of Matter No. 1018-00002 following the successful resolution of the inquiry initiated by the U.S. Food and Drug Administration's Office of Prescription Drug Promotion ("OPDP"), a division of the Center for Drug Evaluation and Research ("CDER"), into the promotional materials and sales-representative communications of Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") concerning its branded pharmaceutical product Zelvara® (trepivant sodium, NDA #214-837). The inquiry was designated by OPDP under reference number OPDP-2023-1847.

The matter is recommended for closure effective February 22, 2024. The FDA issued its close-out and acknowledgment letter on February 19, 2024, confirming that the agency considers the matter resolved on the basis of Penterra's comprehensive corrective actions. No Warning Letter was issued, and no referral was made to the Department of Justice ("DOJ") or the Office of Inspector General ("OIG") of the Department of Health and Human Services.

This memorandum summarizes the final disposition of the matter, the key milestones and events during the engagement, the corrective actions implemented by the Company, the results of the internal investigation, relevant securities-disclosure considerations, the final billing summary, document-retention and privilege-log obligations, and any residual considerations or open items that may warrant attention following matter closure. This document should be maintained with the permanent matter file in accordance with the firm's document-retention policy.

II. MATTER SUMMARY

A. Engagement Overview

Calderwood & Harkness LLP ("the Firm") was engaged on October 30, 2023, by Penterra Pharmaceuticals Corp., a Delaware corporation with its principal executive offices located at 480 Overlook Drive, Suite 700, Summit, New Jersey 07901. Penterra's common stock is publicly traded on the New York Stock Exchange under the ticker symbol PTPH. The engagement was made through the Company's Executive Vice President and General Counsel, Margaret Tan, pursuant to an engagement letter executed on the same date.

The scope of the engagement encompassed the following principal objectives: (i) advising Penterra on the legal implications of, and preparing a comprehensive response to, the OPDP inquiry letter dated October 12, 2023 (reference OPDP-2023-1847), which was received by Penterra on October 16, 2023; (ii) conducting a thorough internal review of Zelvara®-related promotional practices, materials, and sales-representative conduct; and (iii) preparing and submitting a formal written response to the FDA that addressed each of the agency's concerns and set forth a detailed corrective-action plan.

Zelvara® (trepivant sodium), available in 75 mg and 150 mg oral tablets, received FDA approval on October 11, 2019, under NDA #214-837, for the acute treatment of migraine with or without aura in adults. The product is a selective serotonin (5-HT1F) receptor agonist indicated for episodic migraine and represents Penterra's flagship commercial product. For the fiscal year ended December 31, 2022, Zelvara® generated net revenue of approximately $814.6 million, representing approximately 37.4% of Penterra's total revenue of $2.18 billion. Based on reported revenue of $612.3 million for the first three quarters of fiscal year 2023 (Q1 through Q3), annualized 2023 revenue for Zelvara® was projected at approximately $816.4 million, broadly consistent with the prior year's performance and underscoring the product's commercial significance to the Company's overall financial profile. Penterra's approximate market capitalization as of October 2023 was approximately $6.9 billion.

Given the materiality of Zelvara® to Penterra's revenue base and the potential reputational and regulatory consequences of an adverse OPDP outcome, the Company and the Firm treated this matter with the highest priority from the outset of the engagement.

B. The OPDP Inquiry

The OPDP inquiry letter, dated October 12, 2023, was signed by Dr. Carla M. Witherspoon, Pharm.D., Regulatory Review Officer, Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. The letter was addressed to Penterra's Regulatory Affairs department and was received by the Company on October 16, 2023.

The inquiry cited three specific promotional materials from Penterra's Q2–Q3 2023 "Clarity Campaign," a multi-channel promotional initiative developed by Ridgeline Health Analytics LLC ("Ridgeline") under a Statement of Work ("SOW") dated January 9, 2023, with an approved budget of $1.85 million. The Clarity Campaign was executed pursuant to a broader Master Services Agreement between Penterra and Ridgeline dated March 15, 2021, with an annual retainer of $3.4 million. The three cited materials, and the OPDP's specific concerns with respect to each, are described below:

1. Digital Banner Ad (ZVR-2023-BNR-044). This digital display advertisement ran on the MedLinkPro physician education platform from April 15, 2023, through August 31, 2023. The OPDP's inquiry identified two principal deficiencies. First, the banner ad prominently featured the claim "Fastest Onset in Its Class," a comparative superiority claim that lacked adequate substantiation from head-to-head clinical trial data or other scientifically rigorous evidence sufficient to support such a claim under 21 CFR § 202.1(e)(6). Second, the banner ad omitted the hepatotoxicity risk associated with Zelvara®, specifically the incidence of alanine aminotransferase ("ALT") elevations greater than three times the upper limit of normal ("3× ULN"), which occurred in 1.8% of subjects in the pivotal clinical-trial program. This omission constituted a failure to present risk information with a prominence and readability reasonably comparable to the presentation of efficacy information, in violation of 21 CFR § 202.1(e)(5).

2. Physician Email Blast (ZVR-2023-EML-019). This electronic communication was sent on June 7, 2023, to approximately 42,000 neurologists and primary-care physicians. The email presented efficacy data from the Phase III SUMMIT-3 clinical trial using a bar chart with a truncated y-axis, which had the effect of visually exaggerating the efficacy differential between Zelvara® and placebo. The underlying data showed a 2-hour pain-freedom rate of 23.7% for Zelvara® versus 14.2% for placebo (p < 0.001, n = 1,842). While the numerical data themselves were accurate, the OPDP determined that the truncated y-axis presentation was misleading within the meaning of 21 U.S.C. § 352(n), as it created a visual impression of a substantially larger treatment effect than the data supported.

3. Sales Representative Detail Aid (ZVR-2023-DA-007). This printed sales-aid document was approved by Penterra's internal Promotional Review Committee ("PRC") on March 22, 2023, and distributed to the Company's field sales force for use during in-person and virtual physician detailing visits. The detail aid cited the Harmon et al. poster presentation from the American Headache Society Annual Scientific Meeting 2022 as supporting evidence for Zelvara®'s clinical profile. The OPDP's inquiry noted two concerns: (a) the detail aid failed to disclose that the Harmon et al. study was funded by Penterra; and (b) the detail aid failed to disclose that the study lacked a control arm, thereby limiting the conclusions that could be drawn from its results. These omissions were cited as misleading under 21 U.S.C. § 352(n) and 21 CFR § 202.1(e)(6).

In sum, the OPDP alleged the following categories of violations: (i) misleading efficacy claims in violation of 21 U.S.C. § 352(n) and 21 CFR § 202.1(e)(6); (ii) omission and minimization of risk information in violation of 21 CFR § 202.1(e)(5); (iii) unsubstantiated superiority claims; and (iv) misleading graphical presentations of clinical data.

The original response deadline set forth in the inquiry letter was November 15, 2023, providing thirty (30) days from the date of receipt by Penterra. On November 1, 2023, Calderwood & Harkness submitted a written request on behalf of Penterra for a sixty-day extension of the response deadline. The request cited the complexity of the inquiry, the number of materials at issue, and the Company's intention to conduct a comprehensive internal review and implement corrective actions in advance of its response. The FDA granted the extension on November 8, 2023, establishing a new response deadline of January 15, 2024.

C. Engagement Team and Co-Counsel

The Calderwood & Harkness LLP engagement team for this matter consisted of the following attorneys:

• Leonard Cross, Responsible Partner (Tax). Mr. Cross served as the supervising partner with overall responsibility for the engagement.

• Nathaniel Bower, Billing Partner (Bankruptcy & Restructuring). Mr. Bower served as the billing partner and provided oversight on engagement economics and client-relationship management.

• Jeffrey Park, Lead Associate (Litigation (General)). Mr. Park served as the day-to-day lead on the matter, coordinating the internal investigation, supervising document review, and drafting the FDA response.

• Audrey Zhou, Working Associate (Capital Markets). Ms. Zhou provided support on securities-disclosure matters, including the Form 8-K filing and coordination with Penterra's independent auditor.

In addition to the Calderwood & Harkness team, the following co-counsel and consultants were engaged with the express consent of the client:

• Whitfield Bauer & Associates LLP, 1330 Connecticut Avenue NW, Suite 500, Washington, DC 20036. Whitfield Bauer served as FDA regulatory specialist co-counsel. The lead partner on the engagement was Dr. Hannah Whitfield, J.D., Ph.D., a nationally recognized authority on FDA advertising and promotional-labeling regulations. Dr. Whitfield was supported by senior associate Thomas Crane. Whitfield Bauer was engaged with Penterra's written consent effective November 10, 2023, and provided substantive guidance on the regulatory framework, reviewed all draft response materials, and advised on the corrective-action plan.

• Tavrenis Stern Consulting Group LLC, 311 South Wacker Drive, Suite 2400, Chicago, IL 60606. Tavrenis Stern served as the forensic e-discovery and communications-review consultant. The engagement lead was Patricia Okoro. Tavrenis Stern was engaged under the direction of counsel to preserve the privileged nature of the review. Tavrenis Stern's scope included the collection, processing, and hosting of CRM call-note records, emails, and text messages of identified sales representatives, as well as the provision of a review platform and technical support for the Firm's document-review team.

All co-counsel and consultant engagements were structured to maintain the protections of the attorney-client privilege and the work-product doctrine.

III. KEY MILESTONES AND TIMELINE

The following is a chronological summary of the key milestones and events relevant to this matter, from the underlying FDA approval of Zelvara® through the closing of the engagement:

The timeline reflects that the engagement spanned approximately 116 days from opening (October 30, 2023) to closure (February 22, 2024). The Firm's work was substantially front-loaded during the November–January period, reflecting the urgency of the extension request, the internal investigation, and the preparation of the formal FDA response.

IV. FDA DISPOSITION

On February 19, 2024, Penterra Pharmaceuticals Corp. received a close-out letter from the Office of Prescription Drug Promotion, signed by Dr. Carla M. Witherspoon, Pharm.D., Regulatory Review Officer, confirming that OPDP considers the matter designated as OPDP-2023-1847 to be resolved. The close-out letter specifically acknowledged Penterra's cooperation throughout the inquiry process and cited the Company's corrective actions as the basis for the agency's determination to close its file on the matter.

Critically, the following outcomes should be noted for the record:

• No Warning Letter was issued. The issuance of a Warning Letter would have required Penterra to make additional public disclosures and could have triggered further regulatory and commercial consequences, including potential exclusion from certain federal healthcare programs or heightened scrutiny of future NDA supplements.

• No referral was made to the Department of Justice (DOJ) or the Office of Inspector General (OIG) of the Department of Health and Human Services. A referral to DOJ could have resulted in a civil or criminal investigation under the False Claims Act, the Anti-Kickback Statute, or the misbranding provisions of the Federal Food, Drug, and Cosmetic Act. The absence of any such referral represents a highly favorable outcome.

The favorable disposition reflects the FDA's acceptance of the comprehensive seven-point corrective action plan submitted as part of Penterra's January 12, 2024 formal response letter. The response strategy — which emphasized voluntary and proactive corrective measures, transparency regarding the internal investigation findings (including the off-label promotion findings), and the implementation of systemic compliance improvements — was developed collaboratively by the Calderwood & Harkness and Whitfield Bauer teams in close consultation with Penterra's legal, medical affairs, and compliance leadership.

It is the Firm's assessment that several factors contributed to the favorable outcome: (i) the speed with which Penterra withdrew the cited materials (within eighteen days of receipt of the inquiry letter); (ii) the Company's decision to voluntarily disclose the off-label promotion findings, which demonstrated good faith and a commitment to transparency; (iii) the substantive quality and specificity of the corrective-action plan; (iv) the issuance of the corrective "Dear Healthcare Provider" letter before the formal response was submitted; and (v) the Company's completion of sales-force retraining concurrent with the response process.

V. SUMMARY OF CORRECTIVE ACTIONS IMPLEMENTED

The following seven corrective actions were described in Penterra's formal response to the OPDP dated January 12, 2024, and were accepted by the FDA as the basis for closing the inquiry. Each action is summarized below with its implementation date and current status:

1. Immediate Withdrawal of Cited Materials. All three promotional materials identified in the OPDP inquiry — the digital banner ad (ZVR-2023-BNR-044), the physician email blast (ZVR-2023-EML-019), and the sales representative detail aid (ZVR-2023-DA-007) — were withdrawn from circulation and all distribution channels. Withdrawal was completed on November 3, 2023, eighteen days after receipt of the inquiry letter and prior to the engagement of co-counsel or the commencement of the formal internal investigation. The MedLinkPro platform confirmed removal of all digital banner ad impressions. Hard copies of the detail aid were recalled from the field sales force and destroyed pursuant to Penterra's standard document-destruction protocol.

2. Corrective "Dear Healthcare Provider" Letter. A corrective communication was sent on December 11, 2023, to the approximately 42,000 neurologists and primary-care physicians who had received the physician email blast (ZVR-2023-EML-019). The letter was signed by Dr. Rajeev Anand, M.D., Ph.D., Penterra's Chief Medical Officer, and was reviewed and approved by Dr. Hannah Whitfield of Whitfield Bauer & Associates LLP prior to distribution. The letter specifically corrected the misleading bar chart by presenting the SUMMIT-3 efficacy data with a non-truncated y-axis, retracted the "Fastest Onset in Its Class" claim, and provided complete risk information including the hepatotoxicity data (ALT elevations >3× ULN in 1.8% of clinical-trial subjects). Penterra maintained a distribution log confirming delivery.

3. Revised Promotional Review Committee Standard Operating Procedures. Penterra adopted and implemented revised PRC SOPs effective January 2, 2024. The revised SOPs incorporate several significant changes, including: (a) a requirement for unanimous Medical Affairs sign-off on all promotional materials containing efficacy claims or graphical presentations of clinical data, eliminating the prior majority-vote approval mechanism that had permitted the May 18, 2023 override of the Medical Affairs objection; (b) mandatory independent medical-legal review of all comparative or superiority claims prior to PRC consideration; and (c) a requirement that all graphical presentations of clinical data include y-axes beginning at zero unless a deviation is supported by a documented scientific justification approved by the Chief Medical Officer.

4. Sales-Force Retraining. Penterra conducted mandatory promotional-compliance retraining for all 680 field sales representatives. The training program covered FDA promotional-compliance requirements, the Company's revised promotional policies and procedures, the prohibition on off-label promotion, and the specific lessons learned from the OPDP inquiry. Training was delivered through a combination of live virtual sessions and an online learning module with a competency assessment. Completion was documented through Penterra's learning-management system, and a 100% completion rate was achieved by January 31, 2024.

5. Termination of Ridgeline Health Analytics LLC. Penterra issued a notice of termination to Ridgeline Health Analytics LLC on December 18, 2023. In accordance with the 90-day termination clause in the Master Services Agreement dated March 15, 2021, the termination becomes effective on March 15, 2024. The decision to terminate Ridgeline reflected the Firm's findings, discussed in the internal investigation summary below, that Ridgeline's Clarity Campaign SOW lacked provisions requiring independent medical-legal review of claims before submission to Penterra's PRC, contributing to the compliance failures at issue.

6. Engagement of Successor Agency. Penterra has engaged Calloway & March Communications LLC ("Calloway & March") as its successor promotional-services agency, effective March 18, 2024. The Calloway & March engagement letter incorporates enhanced compliance requirements, including independent medical-legal review of all promotional claims and representations prior to submission to Penterra's PRC for approval.

7. Enhanced Monitoring Program. Penterra has implemented a quarterly audit program under which the Medical Affairs department will review a random sample of 10% of field sales-representative interactions (drawn from CRM call notes, recorded detailing sessions, and other available records) to monitor compliance with FDA promotional requirements and Penterra's internal policies. The program is designed to provide ongoing assurance that the corrective measures are being followed and to identify any emerging compliance concerns on a timely basis.

As of the matter close date, corrective actions 1 through 4 have been fully implemented. Corrective action 5 (Ridgeline termination) will become effective on March 15, 2024, and corrective action 6 (Calloway & March engagement) will commence on March 18, 2024; both of these transitions will occur after the closure of this matter and will be managed by Penterra's in-house legal and commercial teams. Corrective action 7 (enhanced monitoring program) is ongoing and will continue indefinitely as part of Penterra's compliance infrastructure.

VI. INTERNAL INVESTIGATION SUMMARY

Calderwood & Harkness LLP conducted a comprehensive internal review of Penterra's Zelvara®-related promotional practices, the results of which are detailed in the privileged Internal Investigation Findings Memorandum dated December 20, 2023, delivered to Margaret Tan, EVP & General Counsel. The investigation was conducted under the direction of counsel and is protected by the attorney-client privilege and the work-product doctrine. The following is a summary of the investigation's scope and key findings.

Scope of Investigation. The internal investigation encompassed the following components:

• Promotional-Materials Review: A comprehensive review of all sixty-seven (67) Zelvara®-branded promotional materials approved by Penterra's Promotional Review Committee during the period from January 1, 2023, through October 16, 2023 (the date of receipt of the OPDP inquiry letter). Each material was assessed against the FDA-approved prescribing information, applicable OPDP guidance documents, and the requirements of 21 U.S.C. § 352(n) and 21 CFR § 202.1.

• PRC Meeting Minutes Review: A review of the minutes from nine (9) PRC meetings held between January and October 2023, with particular attention to the approval deliberations for the three cited materials and any documented internal objections or compliance concerns.

• Forensic Communications Review: A forensic review conducted by Tavrenis Stern Consulting Group LLC, under the direction of counsel, of CRM call-note records, email communications, and text messages of fourteen (14) identified Northeast-region sales representatives. The fourteen representatives were selected based on geographic assignment (Northeast region), call volume during the relevant period, and CRM records suggesting potential compliance concerns. Data was collected, processed, and hosted on Tavrenis Stern's proprietary e-discovery platform.

• Witness Interviews: Interviews of key Penterra personnel were conducted by Jeffrey Park and, in certain instances, with the participation of Dr. Hannah Whitfield of Whitfield Bauer. Interviewees included the following individuals:

• Derek Foss, Vice President, Commercial Operations & Marketing

• Alan Renwick, Director, Promotional Review Committee

• Dr. Lina Gerhardt, Senior Director, Medical Affairs

• Monica Chu, Account Lead at Ridgeline Health Analytics LLC (interviewed with Penterra's consent)

Key Findings. The internal investigation yielded the following principal findings:

• Limited Scope of Material Deficiencies. Of the sixty-seven (67) Zelvara® promotional materials reviewed, only the three materials cited by the OPDP were found to have material compliance deficiencies. The remaining sixty-four (64) materials were determined to be consistent with the FDA-approved prescribing information and applicable regulatory requirements. This finding supported Penterra's position that the Clarity Campaign materials represented an aberration rather than a systemic compliance failure.

• PRC Deliberations and Override of Medical Affairs Objection. Review of the PRC meeting minutes from May 18, 2023, confirmed that Dr. Lina Gerhardt and the Medical Affairs team had raised a specific objection to the truncated y-axis in the physician email blast (ZVR-2023-EML-019), noting that the presentation could be perceived as misleading. The objection was overruled by a 4-3 PRC vote, with the majority taking the position that the truncated y-axis was an accepted convention in medical literature. This finding was a significant factor in the recommendation to revise the PRC SOPs to require unanimous Medical Affairs sign-off.

• Inadequate Substantiation of Superiority Claim. The "Fastest Onset in Its Class" claim featured in the digital banner ad (ZVR-2023-BNR-044) was traced to an unpublished indirect treatment comparison ("ITC") meta-analysis prepared by Keswick Bioanalytics Inc. on behalf of Penterra. The Keswick analysis contained acknowledged methodological limitations, including heterogeneity across the included studies, differences in endpoint definitions, and the absence of direct head-to-head clinical trial data. The analysis did not constitute substantial evidence or substantial clinical experience sufficient to support a comparative superiority claim under OPDP standards.

• Off-Label Promotion by Sales Representatives. The forensic review identified three (3) of the fourteen (14) reviewed Northeast-region sales representatives who made verbal off-label claims regarding Zelvara® efficacy for the treatment of cluster headache, which is not an FDA-approved indication for the product. These off-label statements were documented in CRM call notes from the May through July 2023 time period. While the off-label claims were not the subject of the OPDP inquiry, the Firm recommended, and Penterra agreed, that these findings should be voluntarily disclosed to the FDA as part of the corrective-action plan to demonstrate the Company's commitment to transparency and compliance.

• Ridgeline SOW Deficiency. The Clarity Campaign SOW between Penterra and Ridgeline did not require Ridgeline to conduct or obtain independent medical-legal review of promotional claims and representations before submitting draft materials to Penterra's PRC for review. This gap in the contractual framework contributed to the submission of materials with compliance deficiencies to the PRC and, ultimately, to their approval and dissemination.

The Internal Investigation Findings Memorandum, including supporting exhibits and interview summaries, is maintained in the privileged matter file and should not be disclosed outside the attorney-client relationship absent a specific waiver of privilege by Penterra.

VII. SECURITIES DISCLOSURE

Given Penterra's status as a publicly traded company listed on the New York Stock Exchange, the Firm provided advice on the Company's securities-disclosure obligations in connection with the OPDP inquiry. The following is a summary of the securities-related actions taken during the engagement.

Calderwood & Harkness delivered a securities-disclosure advice memorandum to Margaret Tan on November 3, 2023, analyzing Penterra's disclosure obligations under the Securities Exchange Act of 1934 and applicable SEC regulations. The memorandum concluded that the OPDP inquiry constituted a material regulatory matter warranting disclosure by the Company on a current report. Consistent with this advice, Penterra filed a Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing the receipt of the OPDP inquiry letter. The filing was reviewed by Audrey Zhou and Jeffrey Park prior to submission.

The OPDP inquiry and its resolution were subsequently disclosed in Penterra's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on February 28, 2024. The Form 10-K disclosure described the nature of the inquiry, the Company's corrective actions, and the favorable resolution reflected in the FDA's close-out letter.

In connection with Penterra's financial reporting, Calderwood & Harkness coordinated with Meriden & Cole CPAs LLP, Penterra's independent auditor (engagement partner Susan Nakamura, CPA), regarding contingent-liability footnote considerations under ASC 450 (formerly SFAS No. 5). Given the favorable resolution of the matter — specifically, the absence of a Warning Letter, the absence of any DOJ or OIG referral, and the agency's acceptance of the corrective-action plan — no contingent-liability accrual was required in Penterra's financial statements. The coordination with Meriden & Cole was completed in advance of the Form 10-K filing.

It should be noted that no material adverse impact on Penterra's stock price (NYSE: PTPH) was observed following either the November 6, 2023 Form 8-K filing or the subsequent disclosures. This is consistent with market analysis suggesting that the OPDP inquiry, while requiring disclosure, was not viewed by investors as a significant negative event, particularly given the absence of a Warning Letter or enforcement referral. No pending or threatened securities litigation related to the OPDP inquiry has been identified as of the matter close date.

VIII. FINAL BILLING SUMMARY

A. Calderwood & Harkness LLP

The billing arrangement for this engagement was on an hourly basis, with a blended rate of approximately $785 per hour across the engagement team. The engagement letter included a fee cap of $450,000 for the Firm's fees and expenses.

Final billed fees: $387,240

Fee cap: $450,000

Amount under fee cap: $62,760

The final billed amount reflects the efficient execution of the engagement, including the benefit of the focused scope of the internal investigation (limited to Zelvara® materials from the 2023 calendar year) and the collaborative division of labor with co-counsel Whitfield Bauer, which avoided duplication of effort on regulatory-analysis tasks.

B. Whitfield Bauer & Associates LLP (Co-Counsel)

Whitfield Bauer's fees were billed at the following rates: Dr. Hannah Whitfield at $950 per hour and Thomas Crane at $625 per hour.

Final billed fees: $62,750

Whitfield Bauer's work was concentrated in two principal areas: (i) substantive regulatory analysis and review of draft response materials, and (ii) advisory consultations regarding the corrective-action plan and the corrective "Dear Healthcare Provider" letter.

C. Tavrenis Stern Consulting Group LLC (Forensic Consultant)

Tavrenis Stern's fees were billed on a fixed-fee basis for data collection, processing, and review-platform hosting.

Fees: $87,500

The fixed-fee arrangement encompassed the collection of CRM call-note records, email communications, and text messages from the fourteen identified Northeast-region sales representatives; the processing and deduplication of collected data; and the hosting and maintenance of the e-discovery review platform for the duration of the document-review period.

D. Total Outside Costs

The total outside legal and consulting costs for this matter were as follows:

All invoices have been submitted to Penterra. The final Calderwood & Harkness invoice was transmitted on February 22, 2024, and payment is expected in accordance with standard billing terms set forth in the engagement letter.

IX. DOCUMENT RETENTION AND PRIVILEGE-LOG MAINTENANCE

A. Document-Retention Obligations

All matter files associated with Matter No. 1018-00002, including work product, correspondence, memoranda, research materials, notes, and all other documents generated or received in connection with this engagement, shall be retained in accordance with Calderwood & Harkness's standard document-retention policy. The Firm's policy requires a minimum retention period of seven (7) years from the matter close date. Accordingly, all materials must be retained through at least February 22, 2031.

The matter file includes both paper and electronic records. All electronic files shall be archived in the Firm's document-management system under Matter No. 1018-00002, with appropriate access controls to ensure that privileged and confidential materials are not inadvertently disclosed. Paper files, to the extent they exist, shall be stored in the Firm's off-site records-management facility and indexed to the matter number.

With respect to the forensic data collected and hosted by Tavrenis Stern Consulting Group LLC — including CRM call-note records, email communications, and text messages of the fourteen (14) identified Northeast-region sales representatives — such data shall be preserved in accordance with the document-retention schedule established at the commencement of the engagement. Upon the expiration of the agreed retention period, or upon earlier instruction from the client, the data shall be returned to Penterra or destroyed in accordance with the terms of the Tavrenis Stern engagement letter and the client's written instructions. Tavrenis Stern has been notified of the matter closure and has been instructed to maintain the e-discovery platform data pending further direction.

B. Privilege-Log Maintenance

A comprehensive privilege log was maintained throughout the duration of this matter in accordance with the Privilege and Work-Product Protection Protocol Memorandum dated October 31, 2023. The protocol established procedures for the identification, marking, and segregation of all materials protected by the attorney-client privilege, the work-product doctrine, and any other applicable privileges or protections.

All privileged and work-product materials have been clearly marked as such and are segregated from Penterra's business records. The privilege log documents, for each protected communication or document, the date, author(s), recipient(s), a general description of the subject matter (without disclosing privileged content), and the applicable privilege or protection.

The privilege log should be preserved with the permanent matter file indefinitely, without regard to the standard seven-year retention period, in the event of any future litigation, regulatory action, government investigation, or third-party request involving Penterra's promotional practices, the Zelvara® product, or any subject matter related to OPDP inquiry OPDP-2023-1847. Indefinite retention of the privilege log is recommended because the Company's promotional-practices history may be relevant to future regulatory interactions, and the ability to identify and assert privilege over the documents generated during this engagement could be critical in such contexts.

C. Key Privileged Documents Indexed

The following is a non-exhaustive index of key privileged documents maintained in the matter file:

1. Engagement Letter between Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. (October 30, 2023)

2. Privilege and Work-Product Protection Protocol Memorandum (October 31, 2023)

3. Securities-Disclosure Advice Memorandum (November 3, 2023)

4. Preliminary Assessment Memorandum (November 6, 2023)

5. Internal Investigation Plan Memorandum (November 8, 2023)

6. Co-Counsel Engagement Letter — Whitfield Bauer & Associates LLP (November 10, 2023)

7. Promotional-Labeling Compliance Analysis Memorandum (December 4, 2023)

8. Corrective "Dear Healthcare Provider" Letter (December 11, 2023)

9. Internal Investigation Findings Memorandum (December 20, 2023)

10. Draft FDA Response Letter (January 5, 2024)

11. Final FDA Response Letter as submitted (January 12, 2024)

12. All attorney-client communications with Penterra personnel, including but not limited to Margaret Tan (EVP & General Counsel), Dr. Rajeev Anand (Chief Medical Officer), Christine Holloway, Derek Foss (VP, Commercial Operations & Marketing), Dr. Lina Gerhardt (Senior Director, Medical Affairs), and Alan Renwick (Director, PRC)

13. All communications with co-counsel Whitfield Bauer & Associates LLP made in connection with the provision of legal advice to the client

14. All communications with Tavrenis Stern Consulting Group LLC made at the direction of counsel in connection with the internal investigation

The complete privilege log, which contains a detailed entry for each privileged document and communication, is maintained as a separate appendix to the matter file.

X. RESIDUAL CONSIDERATIONS AND OPEN ITEMS

A. Ongoing Penterra Obligations

Although the OPDP inquiry has been formally resolved and this matter is being closed, certain corrective-action commitments made by Penterra in its formal response to the FDA will continue beyond the matter closure date. These ongoing obligations are the responsibility of Penterra's in-house legal, compliance, and medical affairs teams and do not require further action by Calderwood & Harkness absent a new engagement.

The principal ongoing obligations are as follows:

• Enhanced Monitoring Program. The quarterly audit program, under which Penterra's Medical Affairs department reviews a random 10% sample of field sales-representative interactions, is an ongoing commitment. Penterra should ensure that audit results are documented and that any identified compliance deviations are promptly addressed and reported to the appropriate internal oversight bodies.

• Agency Transition. The termination of Ridgeline Health Analytics LLC becomes effective on March 15, 2024. The engagement of successor agency Calloway & March Communications LLC is scheduled to commence on March 18, 2024. Both of these transitions will occur after the closure of this matter. Penterra should ensure that the transition is managed in a manner that avoids any gap in promotional-compliance oversight and that the Calloway & March engagement incorporates the enhanced compliance requirements described in corrective action 6.

• Revised PRC SOPs. The revised Promotional Review Committee Standard Operating Procedures, effective January 2, 2024, are now embedded in Penterra's compliance infrastructure and should be treated as permanent operational requirements absent a future determination by Penterra's legal and compliance leadership that modifications are warranted.

B. Risk Assessment Going Forward

The favorable resolution of the OPDP inquiry — with no Warning Letter issued and no DOJ or OIG referral — represents the best reasonably achievable outcome for Penterra given the nature and substance of the agency's concerns. However, certain prospective risks warrant acknowledgment:

• Heightened Scrutiny. The existence of OPDP inquiry OPDP-2023-1847 on Penterra's regulatory record means that any future promotional-practices deficiency involving Zelvara® or any other Penterra product could result in heightened FDA scrutiny. OPDP maintains institutional records of prior inquiries and enforcement actions, and a pattern of promotional-compliance issues could result in more severe enforcement outcomes in future interactions, including the issuance of a Warning Letter or a referral for further investigation.

• Continued Compliance Monitoring. Penterra should continue its enhanced compliance-monitoring activities and should consider engaging external counsel or consultants to conduct periodic independent audits of its promotional materials and sales-force practices on at least an annual basis. Such proactive measures would further reduce the risk of future OPDP inquiries and would demonstrate the Company's continued commitment to compliance in any future regulatory interaction.

• Absence of Pending Litigation. As of the matter close date, no pending or threatened private litigation related to the OPDP inquiry, the cited promotional materials, or the off-label promotion findings has been identified. This includes an absence of qui tam actions under the False Claims Act, shareholder derivative actions, and securities class actions. However, Penterra should remain vigilant and promptly notify outside counsel in the event that any such claims or proceedings are initiated.

C. Client Notification

Margaret Tan, EVP & General Counsel of Penterra Pharmaceuticals Corp., has been advised of the Firm's intention to close this matter and has been provided with a copy of the FDA close-out letter dated February 19, 2024. Ms. Tan has expressed the Company's satisfaction with the outcome and the Firm's representation.

The final invoice has been transmitted to Penterra and payment is expected in accordance with the standard payment terms set forth in the engagement letter.

XI. RECOMMENDATION

Based on the foregoing, Matter No. 1018-00002 (Penterra Pharmaceuticals Corp. / FDA OPDP Inquiry OPDP-2023-1847) is hereby recommended for closure effective February 22, 2024, with a matter-status designation of closed_completed.

The OPDP inquiry has been resolved favorably, with no Warning Letter issued and no referral to the Department of Justice or the Office of Inspector General. All engagement deliverables have been completed, all corrective actions have been implemented or are on a defined implementation timeline, all invoices have been submitted, and the document-retention and privilege-log obligations have been established and documented.

No further action is required by Calderwood & Harkness LLP in connection with this matter absent new instruction from the client or a material regulatory development affecting the subject matter of the engagement.

XII. SIGNATURE BLOCK

PREPARED BY:

________________________________________

Jeffrey Park Lead Associate, Litigation (General) Calderwood & Harkness LLP

Date: February 22, 2024

APPROVED BY:

________________________________________

Leonard Cross Responsible Partner Calderwood & Harkness LLP

Date: ________

________________________________________

Nathaniel Bower Billing Partner Calderwood & Harkness LLP

Date: ________

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum and all attachments hereto are protected by the attorney-client privilege and the work-product doctrine. Distribution is limited to the named recipients and authorized personnel of Calderwood & Harkness LLP. Do not copy, distribute, or disclose without the prior written authorization of the Responsible Partner.

Date	Event
October 11, 2019	Zelvara® (trepivant sodium) receives FDA approval under NDA #214-837 for the acute treatment of migraine with or without aura in adults
March 15, 2021	Penterra and Ridgeline Health Analytics LLC execute Master Services Agreement (annual retainer: $3.4 million)
January 9, 2023	Clarity Campaign Statement of Work executed between Penterra and Ridgeline (campaign budget: $1.85 million)
March 22, 2023	Penterra's Promotional Review Committee approves Sales Representative Detail Aid ZVR-2023-DA-007
April 15, 2023	Digital banner ad campaign (ZVR-2023-BNR-044) launches on MedLinkPro platform
May 18, 2023	PRC meeting: truncated y-axis on email blast flagged by Dr. Lina Gerhardt, Senior Director, Medical Affairs, and the Medical Affairs team; material approved by 4-3 PRC vote over Medical Affairs objection
June 7, 2023	Physician email blast (ZVR-2023-EML-019) sent to approximately 42,000 neurologists and primary-care physicians
May – July 2023	Three (3) Northeast-region sales representatives make verbal off-label claims regarding Zelvara® efficacy for cluster headache (not an approved indication), as reflected in CRM call-note records
August 31, 2023	Digital banner ad campaign on MedLinkPro concludes
October 12, 2023	OPDP inquiry letter dated and issued (reference OPDP-2023-1847)
October 16, 2023	Inquiry letter received by Penterra Pharmaceuticals Corp.
October 30, 2023	Calderwood & Harkness LLP engagement opened; engagement letter executed (Matter No. 1018-00002)
November 1, 2023	Extension request submitted to FDA on behalf of Penterra
November 3, 2023	Voluntary withdrawal of all three cited promotional materials completed
November 3, 2023	Calderwood & Harkness securities-disclosure advice memorandum delivered to Penterra
November 6, 2023	Penterra files Form 8-K with the SEC disclosing receipt of the OPDP inquiry
November 8, 2023	FDA grants 60-day extension; new response deadline: January 15, 2024
November 10, 2023	Whitfield Bauer & Associates LLP engaged as FDA regulatory specialist co-counsel
December 4, 2023	Promotional-labeling compliance analysis memorandum delivered to client
December 11, 2023	Corrective "Dear Healthcare Provider" letter sent to approximately 42,000 recipients, signed by Dr. Rajeev Anand, M.D., Ph.D., Chief Medical Officer
December 18, 2023	Notice of termination sent to Ridgeline Health Analytics LLC (effective March 15, 2024, per 90-day termination clause in MSA)
December 20, 2023	Internal investigation findings memorandum delivered to client
January 2, 2024	Revised PRC Standard Operating Procedures become effective, requiring unanimous Medical Affairs sign-off for all efficacy claims and graphical presentations
January 5, 2024	Draft FDA response letter circulated to Penterra for review and comment

January 12, 2024	Penterra's formal response to OPDP submitted to the FDA (3 calendar days before deadline)
January 15, 2024	Extended response deadline expires
January 31, 2024	Mandatory promotional-compliance retraining of all 680 field sales representatives completed (100% completion rate documented)
February 19, 2024	FDA close-out and acknowledgment letter received by Penterra
February 22, 2024	Matter closed
Provider	Amount
Calderwood & Harkness LLP	$387,240
Whitfield Bauer & Associates LLP	$62,750
Tavrenis Stern Consulting Group LLC	$87,500
Total	$537,490

PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege, the work-product doctrine, and all other applicable privileges and protections. It is intended solely for use by the named recipients and authorized personnel of Calderwood & Harkness LLP in connection with Matter No. 1018-00002. Any unauthorized review, use, disclosure, or distribution is strictly prohibited.
CALDERWOOD & HARKNESS LLP 600 Lexington Avenue New York, NY 10022
INTERNAL MEMORANDUM
February 22, 2024
TO: Leonard Cross, Responsible Partner (Tax) Nathaniel Bower, Billing Partner (Bankruptcy & Restructuring)
FROM: Jeffrey Park, Lead Associate (Litigation (General))
CC: Audrey Zhou, Working Associate (Capital Markets)
RE: Matter Closing Memorandum — Penterra Pharmaceuticals Corp. / FDA OPDP Inquiry OPDP-2023-1847
MATTER NUMBER: 1018-00002
CLIENT: Penterra Pharmaceuticals Corp. (NYSE: PTPH) 480 Overlook Drive, Suite 700 Summit, NJ 07901
CLIENT CONTACT: Margaret Tan, Executive Vice President & General Counsel
MATTER STATUS: Closed — Completed
I. PURPOSE
This memorandum formally memorializes the closing of Matter No. 1018-00002 following the successful resolution of the inquiry initiated by the U.S. Food and Drug Administration's Office of Prescription Drug Promotion ("OPDP"), a division of the Center for Drug Evaluation and Research ("CDER"), into the promotional materials and sales-representative communications of Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") concerning its branded pharmaceutical product Zelvara® (trepivant sodium, NDA #214-837). The inquiry was designated by OPDP under reference number OPDP-2023-1847.
The matter is recommended for closure effective February 22, 2024. The FDA issued its close-out and acknowledgment letter on February 19, 2024, confirming that the agency considers the matter resolved on the basis of Penterra's comprehensive corrective actions. No Warning Letter was issued, and no referral was made to the Department of Justice ("DOJ") or the Office of Inspector General ("OIG") of the Department of Health and Human Services.
This memorandum summarizes the final disposition of the matter, the key milestones and events during the engagement, the corrective actions implemented by the Company, the results of the internal investigation, relevant securities-disclosure considerations, the final billing summary, document-retention and privilege-log obligations, and any residual considerations or open items that may warrant attention following matter closure. This document should be maintained with the permanent matter file in accordance with the firm's document-retention policy.
II. MATTER SUMMARY
A. Engagement Overview
Calderwood & Harkness LLP ("the Firm") was engaged on October 30, 2023, by Penterra Pharmaceuticals Corp., a Delaware corporation with its principal executive offices located at 480 Overlook Drive, Suite 700, Summit, New Jersey 07901. Penterra's common stock is publicly traded on the New York Stock Exchange under the ticker symbol PTPH. The engagement was made through the Company's Executive Vice President and General Counsel, Margaret Tan, pursuant to an engagement letter executed on the same date.
The scope of the engagement encompassed the following principal objectives: (i) advising Penterra on the legal implications of, and preparing a comprehensive response to, the OPDP inquiry letter dated October 12, 2023 (reference OPDP-2023-1847), which was received by Penterra on October 16, 2023; (ii) conducting a thorough internal review of Zelvara®-related promotional practices, materials, and sales-representative conduct; and (iii) preparing and submitting a formal written response to the FDA that addressed each of the agency's concerns and set forth a detailed corrective-action plan.
Zelvara® (trepivant sodium), available in 75 mg and 150 mg oral tablets, received FDA approval on October 11, 2019, under NDA #214-837, for the acute treatment of migraine with or without aura in adults. The product is a selective serotonin (5-HT1F) receptor agonist indicated for episodic migraine and represents Penterra's flagship commercial product. For the fiscal year ended December 31, 2022, Zelvara® generated net revenue of approximately $814.6 million, representing approximately 37.4% of Penterra's total revenue of $2.18 billion. Based on reported revenue of $612.3 million for the first three quarters of fiscal year 2023 (Q1 through Q3), annualized 2023 revenue for Zelvara® was projected at approximately $816.4 million, broadly consistent with the prior year's performance and underscoring the product's commercial significance to the Company's overall financial profile. Penterra's approximate market capitalization as of October 2023 was approximately $6.9 billion.
Given the materiality of Zelvara® to Penterra's revenue base and the potential reputational and regulatory consequences of an adverse OPDP outcome, the Company and the Firm treated this matter with the highest priority from the outset of the engagement.
B. The OPDP Inquiry
The OPDP inquiry letter, dated October 12, 2023, was signed by Dr. Carla M. Witherspoon, Pharm.D., Regulatory Review Officer, Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. The letter was addressed to Penterra's Regulatory Affairs department and was received by the Company on October 16, 2023.
The inquiry cited three specific promotional materials from Penterra's Q2–Q3 2023 "Clarity Campaign," a multi-channel promotional initiative developed by Ridgeline Health Analytics LLC ("Ridgeline") under a Statement of Work ("SOW") dated January 9, 2023, with an approved budget of $1.85 million. The Clarity Campaign was executed pursuant to a broader Master Services Agreement between Penterra and Ridgeline dated March 15, 2021, with an annual retainer of $3.4 million. The three cited materials, and the OPDP's specific concerns with respect to each, are described below:
1.  Digital Banner Ad (ZVR-2023-BNR-044). This digital display advertisement ran on the MedLinkPro physician education platform from April 15, 2023, through August 31, 2023. The OPDP's inquiry identified two principal deficiencies. First, the banner ad prominently featured the claim "Fastest Onset in Its Class," a comparative superiority claim that lacked adequate substantiation from head-to-head clinical trial data or other scientifically rigorous evidence sufficient to support such a claim under 21 CFR § 202.1(e)(6). Second, the banner ad omitted the hepatotoxicity risk associated with Zelvara®, specifically the incidence of alanine aminotransferase ("ALT") elevations greater than three times the upper limit of normal ("3× ULN"), which occurred in 1.8% of subjects in the pivotal clinical-trial program. This omission constituted a failure to present risk information with a prominence and readability reasonably comparable to the presentation of efficacy information, in violation of 21 CFR § 202.1(e)(5).
2.  Physician Email Blast (ZVR-2023-EML-019). This electronic communication was sent on June 7, 2023, to approximately 42,000 neurologists and primary-care physicians. The email presented efficacy data from the Phase III SUMMIT-3 clinical trial using a bar chart with a truncated y-axis, which had the effect of visually exaggerating the efficacy differential between Zelvara® and placebo. The underlying data showed a 2-hour pain-freedom rate of 23.7% for Zelvara® versus 14.2% for placebo (p < 0.001, n = 1,842). While the numerical data themselves were accurate, the OPDP determined that the truncated y-axis presentation was misleading within the meaning of 21 U.S.C. § 352(n), as it created a visual impression of a substantially larger treatment effect than the data supported.
3.  Sales Representative Detail Aid (ZVR-2023-DA-007). This printed sales-aid document was approved by Penterra's internal Promotional Review Committee ("PRC") on March 22, 2023, and distributed to the Company's field sales force for use during in-person and virtual physician detailing visits. The detail aid cited the Harmon et al. poster presentation from the American Headache Society Annual Scientific Meeting 2022 as supporting evidence for Zelvara®'s clinical profile. The OPDP's inquiry noted two concerns: (a) the detail aid failed to disclose that the Harmon et al. study was funded by Penterra; and (b) the detail aid failed to disclose that the study lacked a control arm, thereby limiting the conclusions that could be drawn from its results. These omissions were cited as misleading under 21 U.S.C. § 352(n) and 21 CFR § 202.1(e)(6).
In sum, the OPDP alleged the following categories of violations: (i) misleading efficacy claims in violation of 21 U.S.C. § 352(n) and 21 CFR § 202.1(e)(6); (ii) omission and minimization of risk information in violation of 21 CFR § 202.1(e)(5); (iii) unsubstantiated superiority claims; and (iv) misleading graphical presentations of clinical data.
The original response deadline set forth in the inquiry letter was November 15, 2023, providing thirty (30) days from the date of receipt by Penterra. On November 1, 2023, Calderwood & Harkness submitted a written request on behalf of Penterra for a sixty-day extension of the response deadline. The request cited the complexity of the inquiry, the number of materials at issue, and the Company's intention to conduct a comprehensive internal review and implement corrective actions in advance of its response. The FDA granted the extension on November 8, 2023, establishing a new response deadline of January 15, 2024.
C. Engagement Team and Co-Counsel
The Calderwood & Harkness LLP engagement team for this matter consisted of the following attorneys:
•  Leonard Cross, Responsible Partner (Tax). Mr. Cross served as the supervising partner with overall responsibility for the engagement.
•  Nathaniel Bower, Billing Partner (Bankruptcy & Restructuring). Mr. Bower served as the billing partner and provided oversight on engagement economics and client-relationship management.
•  Jeffrey Park, Lead Associate (Litigation (General)). Mr. Park served as the day-to-day lead on the matter, coordinating the internal investigation, supervising document review, and drafting the FDA response.
•  Audrey Zhou, Working Associate (Capital Markets). Ms. Zhou provided support on securities-disclosure matters, including the Form 8-K filing and coordination with Penterra's independent auditor.
In addition to the Calderwood & Harkness team, the following co-counsel and consultants were engaged with the express consent of the client:
•  Whitfield Bauer & Associates LLP, 1330 Connecticut Avenue NW, Suite 500, Washington, DC 20036. Whitfield Bauer served as FDA regulatory specialist co-counsel. The lead partner on the engagement was Dr. Hannah Whitfield, J.D., Ph.D., a nationally recognized authority on FDA advertising and promotional-labeling regulations. Dr. Whitfield was supported by senior associate Thomas Crane. Whitfield Bauer was engaged with Penterra's written consent effective November 10, 2023, and provided substantive guidance on the regulatory framework, reviewed all draft response materials, and advised on the corrective-action plan.
•  Tavrenis Stern Consulting Group LLC, 311 South Wacker Drive, Suite 2400, Chicago, IL 60606. Tavrenis Stern served as the forensic e-discovery and communications-review consultant. The engagement lead was Patricia Okoro. Tavrenis Stern was engaged under the direction of counsel to preserve the privileged nature of the review. Tavrenis Stern's scope included the collection, processing, and hosting of CRM call-note records, emails, and text messages of identified sales representatives, as well as the provision of a review platform and technical support for the Firm's document-review team.
All co-counsel and consultant engagements were structured to maintain the protections of the attorney-client privilege and the work-product doctrine.
III. KEY MILESTONES AND TIMELINE
The following is a chronological summary of the key milestones and events relevant to this matter, from the underlying FDA approval of Zelvara® through the closing of the engagement:
The timeline reflects that the engagement spanned approximately 116 days from opening (October 30, 2023) to closure (February 22, 2024). The Firm's work was substantially front-loaded during the November–January period, reflecting the urgency of the extension request, the internal investigation, and the preparation of the formal FDA response.
IV. FDA DISPOSITION
On February 19, 2024, Penterra Pharmaceuticals Corp. received a close-out letter from the Office of Prescription Drug Promotion, signed by Dr. Carla M. Witherspoon, Pharm.D., Regulatory Review Officer, confirming that OPDP considers the matter designated as OPDP-2023-1847 to be resolved. The close-out letter specifically acknowledged Penterra's cooperation throughout the inquiry process and cited the Company's corrective actions as the basis for the agency's determination to close its file on the matter.
Critically, the following outcomes should be noted for the record:
•  No Warning Letter was issued. The issuance of a Warning Letter would have required Penterra to make additional public disclosures and could have triggered further regulatory and commercial consequences, including potential exclusion from certain federal healthcare programs or heightened scrutiny of future NDA supplements.
•  No referral was made to the Department of Justice (DOJ) or the Office of Inspector General (OIG) of the Department of Health and Human Services. A referral to DOJ could have resulted in a civil or criminal investigation under the False Claims Act, the Anti-Kickback Statute, or the misbranding provisions of the Federal Food, Drug, and Cosmetic Act. The absence of any such referral represents a highly favorable outcome.
The favorable disposition reflects the FDA's acceptance of the comprehensive seven-point corrective action plan submitted as part of Penterra's January 12, 2024 formal response letter. The response strategy — which emphasized voluntary and proactive corrective measures, transparency regarding the internal investigation findings (including the off-label promotion findings), and the implementation of systemic compliance improvements — was developed collaboratively by the Calderwood & Harkness and Whitfield Bauer teams in close consultation with Penterra's legal, medical affairs, and compliance leadership.
It is the Firm's assessment that several factors contributed to the favorable outcome: (i) the speed with which Penterra withdrew the cited materials (within eighteen days of receipt of the inquiry letter); (ii) the Company's decision to voluntarily disclose the off-label promotion findings, which demonstrated good faith and a commitment to transparency; (iii) the substantive quality and specificity of the corrective-action plan; (iv) the issuance of the corrective "Dear Healthcare Provider" letter before the formal response was submitted; and (v) the Company's completion of sales-force retraining concurrent with the response process.
V. SUMMARY OF CORRECTIVE ACTIONS IMPLEMENTED
The following seven corrective actions were described in Penterra's formal response to the OPDP dated January 12, 2024, and were accepted by the FDA as the basis for closing the inquiry. Each action is summarized below with its implementation date and current status:
1.  Immediate Withdrawal of Cited Materials. All three promotional materials identified in the OPDP inquiry — the digital banner ad (ZVR-2023-BNR-044), the physician email blast (ZVR-2023-EML-019), and the sales representative detail aid (ZVR-2023-DA-007) — were withdrawn from circulation and all distribution channels. Withdrawal was completed on November 3, 2023, eighteen days after receipt of the inquiry letter and prior to the engagement of co-counsel or the commencement of the formal internal investigation. The MedLinkPro platform confirmed removal of all digital banner ad impressions. Hard copies of the detail aid were recalled from the field sales force and destroyed pursuant to Penterra's standard document-destruction protocol.
2.  Corrective "Dear Healthcare Provider" Letter. A corrective communication was sent on December 11, 2023, to the approximately 42,000 neurologists and primary-care physicians who had received the physician email blast (ZVR-2023-EML-019). The letter was signed by Dr. Rajeev Anand, M.D., Ph.D., Penterra's Chief Medical Officer, and was reviewed and approved by Dr. Hannah Whitfield of Whitfield Bauer & Associates LLP prior to distribution. The letter specifically corrected the misleading bar chart by presenting the SUMMIT-3 efficacy data with a non-truncated y-axis, retracted the "Fastest Onset in Its Class" claim, and provided complete risk information including the hepatotoxicity data (ALT elevations >3× ULN in 1.8% of clinical-trial subjects). Penterra maintained a distribution log confirming delivery.
3.  Revised Promotional Review Committee Standard Operating Procedures. Penterra adopted and implemented revised PRC SOPs effective January 2, 2024. The revised SOPs incorporate several significant changes, including: (a) a requirement for unanimous Medical Affairs sign-off on all promotional materials containing efficacy claims or graphical presentations of clinical data, eliminating the prior majority-vote approval mechanism that had permitted the May 18, 2023 override of the Medical Affairs objection; (b) mandatory independent medical-legal review of all comparative or superiority claims prior to PRC consideration; and (c) a requirement that all graphical presentations of clinical data include y-axes beginning at zero unless a deviation is supported by a documented scientific justification approved by the Chief Medical Officer.
4.  Sales-Force Retraining. Penterra conducted mandatory promotional-compliance retraining for all 680 field sales representatives. The training program covered FDA promotional-compliance requirements, the Company's revised promotional policies and procedures, the prohibition on off-label promotion, and the specific lessons learned from the OPDP inquiry. Training was delivered through a combination of live virtual sessions and an online learning module with a competency assessment. Completion was documented through Penterra's learning-management system, and a 100% completion rate was achieved by January 31, 2024.
5.  Termination of Ridgeline Health Analytics LLC. Penterra issued a notice of termination to Ridgeline Health Analytics LLC on December 18, 2023. In accordance with the 90-day termination clause in the Master Services Agreement dated March 15, 2021, the termination becomes effective on March 15, 2024. The decision to terminate Ridgeline reflected the Firm's findings, discussed in the internal investigation summary below, that Ridgeline's Clarity Campaign SOW lacked provisions requiring independent medical-legal review of claims before submission to Penterra's PRC, contributing to the compliance failures at issue.
6.  Engagement of Successor Agency. Penterra has engaged Calloway & March Communications LLC ("Calloway & March") as its successor promotional-services agency, effective March 18, 2024. The Calloway & March engagement letter incorporates enhanced compliance requirements, including independent medical-legal review of all promotional claims and representations prior to submission to Penterra's PRC for approval.
7.  Enhanced Monitoring Program. Penterra has implemented a quarterly audit program under which the Medical Affairs department will review a random sample of 10% of field sales-representative interactions (drawn from CRM call notes, recorded detailing sessions, and other available records) to monitor compliance with FDA promotional requirements and Penterra's internal policies. The program is designed to provide ongoing assurance that the corrective measures are being followed and to identify any emerging compliance concerns on a timely basis.
As of the matter close date, corrective actions 1 through 4 have been fully implemented. Corrective action 5 (Ridgeline termination) will become effective on March 15, 2024, and corrective action 6 (Calloway & March engagement) will commence on March 18, 2024; both of these transitions will occur after the closure of this matter and will be managed by Penterra's in-house legal and commercial teams. Corrective action 7 (enhanced monitoring program) is ongoing and will continue indefinitely as part of Penterra's compliance infrastructure.
VI. INTERNAL INVESTIGATION SUMMARY
Calderwood & Harkness LLP conducted a comprehensive internal review of Penterra's Zelvara®-related promotional practices, the results of which are detailed in the privileged Internal Investigation Findings Memorandum dated December 20, 2023, delivered to Margaret Tan, EVP & General Counsel. The investigation was conducted under the direction of counsel and is protected by the attorney-client privilege and the work-product doctrine. The following is a summary of the investigation's scope and key findings.
Scope of Investigation. The internal investigation encompassed the following components:
•  Promotional-Materials Review: A comprehensive review of all sixty-seven (67) Zelvara®-branded promotional materials approved by Penterra's Promotional Review Committee during the period from January 1, 2023, through October 16, 2023 (the date of receipt of the OPDP inquiry letter). Each material was assessed against the FDA-approved prescribing information, applicable OPDP guidance documents, and the requirements of 21 U.S.C. § 352(n) and 21 CFR § 202.1.
•  PRC Meeting Minutes Review: A review of the minutes from nine (9) PRC meetings held between January and October 2023, with particular attention to the approval deliberations for the three cited materials and any documented internal objections or compliance concerns.
•  Forensic Communications Review: A forensic review conducted by Tavrenis Stern Consulting Group LLC, under the direction of counsel, of CRM call-note records, email communications, and text messages of fourteen (14) identified Northeast-region sales representatives. The fourteen representatives were selected based on geographic assignment (Northeast region), call volume during the relevant period, and CRM records suggesting potential compliance concerns. Data was collected, processed, and hosted on Tavrenis Stern's proprietary e-discovery platform.
•  Witness Interviews: Interviews of key Penterra personnel were conducted by Jeffrey Park and, in certain instances, with the participation of Dr. Hannah Whitfield of Whitfield Bauer. Interviewees included the following individuals:
•  Derek Foss, Vice President, Commercial Operations & Marketing
•  Alan Renwick, Director, Promotional Review Committee
•  Dr. Lina Gerhardt, Senior Director, Medical Affairs
•  Monica Chu, Account Lead at Ridgeline Health Analytics LLC (interviewed with Penterra's consent)
Key Findings. The internal investigation yielded the following principal findings:
•  Limited Scope of Material Deficiencies. Of the sixty-seven (67) Zelvara® promotional materials reviewed, only the three materials cited by the OPDP were found to have material compliance deficiencies. The remaining sixty-four (64) materials were determined to be consistent with the FDA-approved prescribing information and applicable regulatory requirements. This finding supported Penterra's position that the Clarity Campaign materials represented an aberration rather than a systemic compliance failure.
•  PRC Deliberations and Override of Medical Affairs Objection. Review of the PRC meeting minutes from May 18, 2023, confirmed that Dr. Lina Gerhardt and the Medical Affairs team had raised a specific objection to the truncated y-axis in the physician email blast (ZVR-2023-EML-019), noting that the presentation could be perceived as misleading. The objection was overruled by a 4-3 PRC vote, with the majority taking the position that the truncated y-axis was an accepted convention in medical literature. This finding was a significant factor in the recommendation to revise the PRC SOPs to require unanimous Medical Affairs sign-off.
•  Inadequate Substantiation of Superiority Claim. The "Fastest Onset in Its Class" claim featured in the digital banner ad (ZVR-2023-BNR-044) was traced to an unpublished indirect treatment comparison ("ITC") meta-analysis prepared by Keswick Bioanalytics Inc. on behalf of Penterra. The Keswick analysis contained acknowledged methodological limitations, including heterogeneity across the included studies, differences in endpoint definitions, and the absence of direct head-to-head clinical trial data. The analysis did not constitute substantial evidence or substantial clinical experience sufficient to support a comparative superiority claim under OPDP standards.
•  Off-Label Promotion by Sales Representatives. The forensic review identified three (3) of the fourteen (14) reviewed Northeast-region sales representatives who made verbal off-label claims regarding Zelvara® efficacy for the treatment of cluster headache, which is not an FDA-approved indication for the product. These off-label statements were documented in CRM call notes from the May through July 2023 time period. While the off-label claims were not the subject of the OPDP inquiry, the Firm recommended, and Penterra agreed, that these findings should be voluntarily disclosed to the FDA as part of the corrective-action plan to demonstrate the Company's commitment to transparency and compliance.
•  Ridgeline SOW Deficiency. The Clarity Campaign SOW between Penterra and Ridgeline did not require Ridgeline to conduct or obtain independent medical-legal review of promotional claims and representations before submitting draft materials to Penterra's PRC for review. This gap in the contractual framework contributed to the submission of materials with compliance deficiencies to the PRC and, ultimately, to their approval and dissemination.
The Internal Investigation Findings Memorandum, including supporting exhibits and interview summaries, is maintained in the privileged matter file and should not be disclosed outside the attorney-client relationship absent a specific waiver of privilege by Penterra.
VII. SECURITIES DISCLOSURE
Given Penterra's status as a publicly traded company listed on the New York Stock Exchange, the Firm provided advice on the Company's securities-disclosure obligations in connection with the OPDP inquiry. The following is a summary of the securities-related actions taken during the engagement.
Calderwood & Harkness delivered a securities-disclosure advice memorandum to Margaret Tan on November 3, 2023, analyzing Penterra's disclosure obligations under the Securities Exchange Act of 1934 and applicable SEC regulations. The memorandum concluded that the OPDP inquiry constituted a material regulatory matter warranting disclosure by the Company on a current report. Consistent with this advice, Penterra filed a Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing the receipt of the OPDP inquiry letter. The filing was reviewed by Audrey Zhou and Jeffrey Park prior to submission.
The OPDP inquiry and its resolution were subsequently disclosed in Penterra's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on February 28, 2024. The Form 10-K disclosure described the nature of the inquiry, the Company's corrective actions, and the favorable resolution reflected in the FDA's close-out letter.
In connection with Penterra's financial reporting, Calderwood & Harkness coordinated with Meriden & Cole CPAs LLP, Penterra's independent auditor (engagement partner Susan Nakamura, CPA), regarding contingent-liability footnote considerations under ASC 450 (formerly SFAS No. 5). Given the favorable resolution of the matter — specifically, the absence of a Warning Letter, the absence of any DOJ or OIG referral, and the agency's acceptance of the corrective-action plan — no contingent-liability accrual was required in Penterra's financial statements. The coordination with Meriden & Cole was completed in advance of the Form 10-K filing.
It should be noted that no material adverse impact on Penterra's stock price (NYSE: PTPH) was observed following either the November 6, 2023 Form 8-K filing or the subsequent disclosures. This is consistent with market analysis suggesting that the OPDP inquiry, while requiring disclosure, was not viewed by investors as a significant negative event, particularly given the absence of a Warning Letter or enforcement referral. No pending or threatened securities litigation related to the OPDP inquiry has been identified as of the matter close date.
VIII. FINAL BILLING SUMMARY
A. Calderwood & Harkness LLP
The billing arrangement for this engagement was on an hourly basis, with a blended rate of approximately $785 per hour across the engagement team. The engagement letter included a fee cap of $450,000 for the Firm's fees and expenses.
Final billed fees: $387,240
Fee cap: $450,000
Amount under fee cap: $62,760
The final billed amount reflects the efficient execution of the engagement, including the benefit of the focused scope of the internal investigation (limited to Zelvara® materials from the 2023 calendar year) and the collaborative division of labor with co-counsel Whitfield Bauer, which avoided duplication of effort on regulatory-analysis tasks.
B. Whitfield Bauer & Associates LLP (Co-Counsel)
Whitfield Bauer's fees were billed at the following rates: Dr. Hannah Whitfield at $950 per hour and Thomas Crane at $625 per hour.
Final billed fees: $62,750
Whitfield Bauer's work was concentrated in two principal areas: (i) substantive regulatory analysis and review of draft response materials, and (ii) advisory consultations regarding the corrective-action plan and the corrective "Dear Healthcare Provider" letter.
C. Tavrenis Stern Consulting Group LLC (Forensic Consultant)
Tavrenis Stern's fees were billed on a fixed-fee basis for data collection, processing, and review-platform hosting.
Fees: $87,500
The fixed-fee arrangement encompassed the collection of CRM call-note records, email communications, and text messages from the fourteen identified Northeast-region sales representatives; the processing and deduplication of collected data; and the hosting and maintenance of the e-discovery review platform for the duration of the document-review period.
D. Total Outside Costs
The total outside legal and consulting costs for this matter were as follows:
All invoices have been submitted to Penterra. The final Calderwood & Harkness invoice was transmitted on February 22, 2024, and payment is expected in accordance with standard billing terms set forth in the engagement letter.
IX. DOCUMENT RETENTION AND PRIVILEGE-LOG MAINTENANCE
A. Document-Retention Obligations
All matter files associated with Matter No. 1018-00002, including work product, correspondence, memoranda, research materials, notes, and all other documents generated or received in connection with this engagement, shall be retained in accordance with Calderwood & Harkness's standard document-retention policy. The Firm's policy requires a minimum retention period of seven (7) years from the matter close date. Accordingly, all materials must be retained through at least February 22, 2031.
The matter file includes both paper and electronic records. All electronic files shall be archived in the Firm's document-management system under Matter No. 1018-00002, with appropriate access controls to ensure that privileged and confidential materials are not inadvertently disclosed. Paper files, to the extent they exist, shall be stored in the Firm's off-site records-management facility and indexed to the matter number.
With respect to the forensic data collected and hosted by Tavrenis Stern Consulting Group LLC — including CRM call-note records, email communications, and text messages of the fourteen (14) identified Northeast-region sales representatives — such data shall be preserved in accordance with the document-retention schedule established at the commencement of the engagement. Upon the expiration of the agreed retention period, or upon earlier instruction from the client, the data shall be returned to Penterra or destroyed in accordance with the terms of the Tavrenis Stern engagement letter and the client's written instructions. Tavrenis Stern has been notified of the matter closure and has been instructed to maintain the e-discovery platform data pending further direction.
B. Privilege-Log Maintenance
A comprehensive privilege log was maintained throughout the duration of this matter in accordance with the Privilege and Work-Product Protection Protocol Memorandum dated October 31, 2023. The protocol established procedures for the identification, marking, and segregation of all materials protected by the attorney-client privilege, the work-product doctrine, and any other applicable privileges or protections.
All privileged and work-product materials have been clearly marked as such and are segregated from Penterra's business records. The privilege log documents, for each protected communication or document, the date, author(s), recipient(s), a general description of the subject matter (without disclosing privileged content), and the applicable privilege or protection.
The privilege log should be preserved with the permanent matter file indefinitely, without regard to the standard seven-year retention period, in the event of any future litigation, regulatory action, government investigation, or third-party request involving Penterra's promotional practices, the Zelvara® product, or any subject matter related to OPDP inquiry OPDP-2023-1847. Indefinite retention of the privilege log is recommended because the Company's promotional-practices history may be relevant to future regulatory interactions, and the ability to identify and assert privilege over the documents generated during this engagement could be critical in such contexts.
C. Key Privileged Documents Indexed
The following is a non-exhaustive index of key privileged documents maintained in the matter file:
1.  Engagement Letter between Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. (October 30, 2023)
2.  Privilege and Work-Product Protection Protocol Memorandum (October 31, 2023)
3.  Securities-Disclosure Advice Memorandum (November 3, 2023)
4.  Preliminary Assessment Memorandum (November 6, 2023)
5.  Internal Investigation Plan Memorandum (November 8, 2023)
6.  Co-Counsel Engagement Letter — Whitfield Bauer & Associates LLP (November 10, 2023)
7.  Promotional-Labeling Compliance Analysis Memorandum (December 4, 2023)
8.  Corrective "Dear Healthcare Provider" Letter (December 11, 2023)
9.  Internal Investigation Findings Memorandum (December 20, 2023)
10.  Draft FDA Response Letter (January 5, 2024)
11.  Final FDA Response Letter as submitted (January 12, 2024)
12.  All attorney-client communications with Penterra personnel, including but not limited to Margaret Tan (EVP & General Counsel), Dr. Rajeev Anand (Chief Medical Officer), Christine Holloway, Derek Foss (VP, Commercial Operations & Marketing), Dr. Lina Gerhardt (Senior Director, Medical Affairs), and Alan Renwick (Director, PRC)
13.  All communications with co-counsel Whitfield Bauer & Associates LLP made in connection with the provision of legal advice to the client
14.  All communications with Tavrenis Stern Consulting Group LLC made at the direction of counsel in connection with the internal investigation
The complete privilege log, which contains a detailed entry for each privileged document and communication, is maintained as a separate appendix to the matter file.
X. RESIDUAL CONSIDERATIONS AND OPEN ITEMS
A. Ongoing Penterra Obligations
Although the OPDP inquiry has been formally resolved and this matter is being closed, certain corrective-action commitments made by Penterra in its formal response to the FDA will continue beyond the matter closure date. These ongoing obligations are the responsibility of Penterra's in-house legal, compliance, and medical affairs teams and do not require further action by Calderwood & Harkness absent a new engagement.
The principal ongoing obligations are as follows:
•  Enhanced Monitoring Program. The quarterly audit program, under which Penterra's Medical Affairs department reviews a random 10% sample of field sales-representative interactions, is an ongoing commitment. Penterra should ensure that audit results are documented and that any identified compliance deviations are promptly addressed and reported to the appropriate internal oversight bodies.
•  Agency Transition. The termination of Ridgeline Health Analytics LLC becomes effective on March 15, 2024. The engagement of successor agency Calloway & March Communications LLC is scheduled to commence on March 18, 2024. Both of these transitions will occur after the closure of this matter. Penterra should ensure that the transition is managed in a manner that avoids any gap in promotional-compliance oversight and that the Calloway & March engagement incorporates the enhanced compliance requirements described in corrective action 6.
•  Revised PRC SOPs. The revised Promotional Review Committee Standard Operating Procedures, effective January 2, 2024, are now embedded in Penterra's compliance infrastructure and should be treated as permanent operational requirements absent a future determination by Penterra's legal and compliance leadership that modifications are warranted.
B. Risk Assessment Going Forward
The favorable resolution of the OPDP inquiry — with no Warning Letter issued and no DOJ or OIG referral — represents the best reasonably achievable outcome for Penterra given the nature and substance of the agency's concerns. However, certain prospective risks warrant acknowledgment:
•  Heightened Scrutiny. The existence of OPDP inquiry OPDP-2023-1847 on Penterra's regulatory record means that any future promotional-practices deficiency involving Zelvara® or any other Penterra product could result in heightened FDA scrutiny. OPDP maintains institutional records of prior inquiries and enforcement actions, and a pattern of promotional-compliance issues could result in more severe enforcement outcomes in future interactions, including the issuance of a Warning Letter or a referral for further investigation.
•  Continued Compliance Monitoring. Penterra should continue its enhanced compliance-monitoring activities and should consider engaging external counsel or consultants to conduct periodic independent audits of its promotional materials and sales-force practices on at least an annual basis. Such proactive measures would further reduce the risk of future OPDP inquiries and would demonstrate the Company's continued commitment to compliance in any future regulatory interaction.
•  Absence of Pending Litigation. As of the matter close date, no pending or threatened private litigation related to the OPDP inquiry, the cited promotional materials, or the off-label promotion findings has been identified. This includes an absence of qui tam actions under the False Claims Act, shareholder derivative actions, and securities class actions. However, Penterra should remain vigilant and promptly notify outside counsel in the event that any such claims or proceedings are initiated.
C. Client Notification
Margaret Tan, EVP & General Counsel of Penterra Pharmaceuticals Corp., has been advised of the Firm's intention to close this matter and has been provided with a copy of the FDA close-out letter dated February 19, 2024. Ms. Tan has expressed the Company's satisfaction with the outcome and the Firm's representation.
The final invoice has been transmitted to Penterra and payment is expected in accordance with the standard payment terms set forth in the engagement letter.
XI. RECOMMENDATION
Based on the foregoing, Matter No. 1018-00002 (Penterra Pharmaceuticals Corp. / FDA OPDP Inquiry OPDP-2023-1847) is hereby recommended for closure effective February 22, 2024, with a matter-status designation of closed_completed.
The OPDP inquiry has been resolved favorably, with no Warning Letter issued and no referral to the Department of Justice or the Office of Inspector General. All engagement deliverables have been completed, all corrective actions have been implemented or are on a defined implementation timeline, all invoices have been submitted, and the document-retention and privilege-log obligations have been established and documented.
No further action is required by Calderwood & Harkness LLP in connection with this matter absent new instruction from the client or a material regulatory development affecting the subject matter of the engagement.
XII. SIGNATURE BLOCK
PREPARED BY:
________________________________________
Jeffrey Park Lead Associate, Litigation (General) Calderwood & Harkness LLP
Date: February 22, 2024
APPROVED BY:
________________________________________
Leonard Cross Responsible Partner Calderwood & Harkness LLP
Date: ________
________________________________________
Nathaniel Bower Billing Partner Calderwood & Harkness LLP
Date: ________
PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum and all attachments hereto are protected by the attorney-client privilege and the work-product doctrine. Distribution is limited to the named recipients and authorized personnel of Calderwood & Harkness LLP. Do not copy, distribute, or disclose without the prior written authorization of the Responsible Partner.
Date | Event
October 11, 2019 | Zelvara® (trepivant sodium) receives FDA approval under NDA #214-837 for the acute treatment of migraine with or without aura in adults
March 15, 2021 | Penterra and Ridgeline Health Analytics LLC execute Master Services Agreement (annual retainer: $3.4 million)
January 9, 2023 | Clarity Campaign Statement of Work executed between Penterra and Ridgeline (campaign budget: $1.85 million)
March 22, 2023 | Penterra's Promotional Review Committee approves Sales Representative Detail Aid ZVR-2023-DA-007
April 15, 2023 | Digital banner ad campaign (ZVR-2023-BNR-044) launches on MedLinkPro platform
May 18, 2023 | PRC meeting: truncated y-axis on email blast flagged by Dr. Lina Gerhardt, Senior Director, Medical Affairs, and the Medical Affairs team; material approved by 4-3 PRC vote over Medical Affairs objection
June 7, 2023 | Physician email blast (ZVR-2023-EML-019) sent to approximately 42,000 neurologists and primary-care physicians
May – July 2023 | Three (3) Northeast-region sales representatives make verbal off-label claims regarding Zelvara® efficacy for cluster headache (not an approved indication), as reflected in CRM call-note records
August 31, 2023 | Digital banner ad campaign on MedLinkPro concludes
October 12, 2023 | OPDP inquiry letter dated and issued (reference OPDP-2023-1847)
October 16, 2023 | Inquiry letter received by Penterra Pharmaceuticals Corp.
October 30, 2023 | Calderwood & Harkness LLP engagement opened; engagement letter executed (Matter No. 1018-00002)
November 1, 2023 | Extension request submitted to FDA on behalf of Penterra
November 3, 2023 | Voluntary withdrawal of all three cited promotional materials completed
November 3, 2023 | Calderwood & Harkness securities-disclosure advice memorandum delivered to Penterra
November 6, 2023 | Penterra files Form 8-K with the SEC disclosing receipt of the OPDP inquiry
November 8, 2023 | FDA grants 60-day extension; new response deadline: January 15, 2024
November 10, 2023 | Whitfield Bauer & Associates LLP engaged as FDA regulatory specialist co-counsel
December 4, 2023 | Promotional-labeling compliance analysis memorandum delivered to client
December 11, 2023 | Corrective "Dear Healthcare Provider" letter sent to approximately 42,000 recipients, signed by Dr. Rajeev Anand, M.D., Ph.D., Chief Medical Officer
December 18, 2023 | Notice of termination sent to Ridgeline Health Analytics LLC (effective March 15, 2024, per 90-day termination clause in MSA)
December 20, 2023 | Internal investigation findings memorandum delivered to client
January 2, 2024 | Revised PRC Standard Operating Procedures become effective, requiring unanimous Medical Affairs sign-off for all efficacy claims and graphical presentations
January 5, 2024 | Draft FDA response letter circulated to Penterra for review and comment
January 12, 2024 | Penterra's formal response to OPDP submitted to the FDA (3 calendar days before deadline)
January 15, 2024 | Extended response deadline expires
January 31, 2024 | Mandatory promotional-compliance retraining of all 680 field sales representatives completed (100% completion rate documented)
February 19, 2024 | FDA close-out and acknowledgment letter received by Penterra
February 22, 2024 | Matter closed
Provider | Amount
Calderwood & Harkness LLP | $387,240
Whitfield Bauer & Associates LLP | $62,750
Tavrenis Stern Consulting Group LLC | $87,500
Total | $537,490

INTERNAL MEMORANDUM

MATTER NUMBER: 1018-00002

I. PURPOSE

II. MATTER SUMMARY

III. KEY MILESTONES AND TIMELINE

IV. FDA DISPOSITION

V. SUMMARY OF CORRECTIVE ACTIONS IMPLEMENTED

VI. INTERNAL INVESTIGATION SUMMARY

VII. SECURITIES DISCLOSURE

VIII. FINAL BILLING SUMMARY

IX. DOCUMENT RETENTION AND PRIVILEGE-LOG MAINTENANCE

X. RESIDUAL CONSIDERATIONS AND OPEN ITEMS

XI. RECOMMENDATION

XII. SIGNATURE BLOCK

PREPARED BY:

APPROVED BY:

Record

Parties

Dates

Amounts